Role of interferon tests (interferon-gamma release assays) in the screening of latent tuberculosis before the prescription of anti-TNF agents: The point;Place des tests à l'interféron (IGRAs) dans le dépistage de la tuberculose latente (TBL) avant prescription d'agents anti-TNF: Le point

Revue du Rhumatisme (Edition Francaise)

Volumn 78, Issue 2, 2011, Pages 116-121

  Lioté, Huguette ^a   Lioté, Frédéric ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952581841     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2010.09.005     Document Type: Short Survey

References (51)

1. J. Keane, S. Gershon, and R.P. Wise Tuberculosis associated with infliximab, a tumor necrotising factor neutralizing agent N Engl J Med 345 2001 1098 1104
2. M.A. Gardam, and E.C. Keystone Anti-TNF agents and tuberculosis risk: mechanism of action and clinical management Lancet Infect Dis 3 2003 148 155 (Pubitemid 36278124)
3. S. Ehlers Why does TNF-targeted therapy reactivate tuberculosis? J Rheumatol 32 Suppl. 74 2005 35 39 (Pubitemid 40365779)
4. W. Hanekom, B. Abel, and T. Scriba Immunological protection against tuberculosis SAMJ 97 2007 973 977 (Pubitemid 350027952)
5. H. Lioté Tuberculose, agents anti-TNF et autres immunosuppresseurs: évolution des stratégies de prévention Rev Mal Resp 25 2008 137 150
6. F. Wolfe, K. Michaud, and J. Anderson Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy Arthritis Rheum 50 2004 372 379 (Pubitemid 38198820)
7. J.J. Gomez-Reino, L. Carmona, and V.R. Valverde Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis Rheum 48 2003 2122 2127 (Pubitemid 36959191)
8. L. Carmona, J.J. Gomez-Reino, and V. Rodriguez-Valverde Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 2005 1766 1772 (Pubitemid 40852885)
9. J. Askling, C.M. Fored, and L. Brandt Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden Arthritis Rheum 52 2005 1986 1992 (Pubitemid 40994319)
10. S.S. Seong, C.B. Choi, and J.H. Woo Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers J Rheumatol 34 2007 706 711
11. R.S. Wallis Reactivation of latent tuberculosis by TNF blockade: the role of interferon γ J Investig Dermatol Symp Proc 12 2007 16 21 (Pubitemid 46763028)
12. F. Tubach, D. Salmon, and P. Ravaud Risk of tuberculosis is higher with antitumor necrosis factor antibody therapy than with soluble tumor necrosis factor receptor therapy Arthritis Rheum 60 2009 1884 1894
13. W.G. Dixon, K.L. Hyrich, and K.D. Watson Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the british society for rheumatology biologics register (BSRBR) Ann Rheum Dis 69 2010 522 528
14. J. Harris, S. Master, and S. De Haro Th1-Th2 polarization and autophagy in the control of intracellular mycobacteria by macrophages Vet Imm Imm 128 2009 37 43
15. D.E. Furst, J. Cush, and F. Kaufmann Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents Ann Rheum Dis 61 2002 62 63
16. J. Ledingham, C. Deighton British Society for Rheumatology: standards, guidelines and Audit Working Group Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology (Oxford) 44 2005 157 163 (Pubitemid 40277395)
17. www.AFSSAPS.sante.fr.
18. Y. Zabana, E. Domnech, and A.L. San Román Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy Inflamm Bowel Dis 14 2008 1387 1391
19. Gómez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:756-61. (Pubitemid 46932080)
20. I. Hanta, S. Ozbek, and S. Kuleci Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha Clin Rheumatol 26 2007 1867 1870 (Pubitemid 47516966)
21. Bray MG, Poulain C, Dougados M, et al. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010; doi:10.1016/j.jbspin.2009.10.012.
22. J. Vanhoof, S. Landewe, and E. Van Wijngaerden High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and antitumour necrosis factor inhibitors Ann Rheum Dis 62 2003 1241 1242 (Pubitemid 37500639)
23. A. Mor, C.O. Bingham, and M. Kishimoto Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic Ann Rheum Dis 67 2008 462 465 (Pubitemid 351498424)
24. D. Larrey TNF a-antagonist hepatotoxicity Joint Bone Spine 75 2008 1208 1210
25. V. Theis, and J. Rodes Review article: minimizing tuberculosis during anti-TNF-a treatment of inflammatory bowel disease Aliment Pharmacol Ther 27 2008 19 30 (Pubitemid 350212629)
26. A. Tostmann, M.J. Boeree, and R.E. Aarnoutse Antituberculosis drug-induced hepatotoxicity: concise up-to-date review J Gastroenterol Hepatol 23 2008 192 202 (Pubitemid 351257678)
27. L. Sichletidis, L. Settas, and D. Spyratos Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Int J Tuberc Lung Dis 10 2006 1127 1132 (Pubitemid 44519351)
28. A. Raval, G. Akhavan-Toyserkani, and A. Brinker Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab Ann Intern Med 147 2007 699 702 (Pubitemid 351664465)
29. J.L. Hermann, N. Simonney, and P. Lagrange Avantages et limites des tests sanguins in vitro lymphocytes T/interféron gamma comparativement au test intradermique la tuberculine pour le diagnostic de tuberculose Rev Fr Allergol Immunol Clin 46 2006 543 547 (Pubitemid 44708504)
30. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active tuberculosis - a meta-analysis. Chest 2009;137:952-68.
31. U. Mack, G.B. Migliori, and M. Sester TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement Eur Respir J 33 2009 956 973
32. M. Bocchino, A. Matarese, and B. Bellofiore Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment Eur J Clin Microbiol Infect Dis 27 2008 907 913
33. D. Ponce de Leon, E. Acevedo-Vasquez, and S. Alvizuri Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population J Rheumatol 35 2008 776 781 (Pubitemid 351747116)
34. D. Vassilopoulos, N. Stamoulis, and E. Hadziyannis Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for antitumor necrosis factor treatment J Rheumatol 35 2008 1271 1276 (Pubitemid 352000770)
35. G. Matulis, P. Jüni, and P.M. Villiger Detection of latent tuberculosis in immunosuppressed patients with auto-immune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay Ann Rheum Dis 67 2008 84 90
36. N. Cobanoglu, U. Ozcelik, and U. Kalyoncu Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers Int J Tuberc Lung Dis 11 2007 1177 1182 (Pubitemid 350146297)
37. A. Pratt, K. Nicholl, and L. Kay Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience Rheumatology (Oxford) 46 2007 1035 1036 (Pubitemid 47062518)
38. S.M. Behar, D.S. Shin, and A. Maier Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy J Rheumatol 36 2009 546 551
39. A.M. Schoepfer, B. Flogerzi, and S. Fallegger Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease Am J Gastroenterol 103 2008 2799 2806
40. G. Ferrara, M. Losi, and P. Roversi New tools for a better diagnosis of latent tuberculosis infection Recenti Prog Med 97 2006 123 128
41. R. Dinser, M. Fousse, and U. Sester Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay Rheumatology (Oxford) 47 2008 212 218 (Pubitemid 351168235)
42. J.D. Greenberg, S.M. Reddy, and S.G. Schloss Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis J Rheumatol 35 2008 770 775 (Pubitemid 351747115)
43. B. Soborg, M. Ruhwald, and M.L. Hetland Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases J Rheumatol 36 2009 1876 1884
44. F. Bartalesi, S. Vicidomini, and D. Goletti QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in auto-immune diseases Eur Respir J 33 2009 586 593
45. J. Sellam, H. Hamdi, and C. Roy Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy Ann Rheum Dis 66 2007 1610 1615 (Pubitemid 350205449)
46. J. Martin, C. Walsh, and A. Gibbs Comparison of interferon (gamma) release assays and conventional screening tests before tumour necrosis factor (alpha) blockade in patients with inflammatory arthritis Ann Rheum Dis 69 2010 181 185
47. M. Ruhwald, M. Bjerregaard-Andersen, and P. Rabna CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7. 7 Microbes Infect 9 2007 806 812 (Pubitemid 46901043)
48. E. Laffitte, J.P. Janssens, and P. Roux-Lombard Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay versus tuberculin skin test Br J Dermatol 161 2009 797 800
49. M. Pai, J. Minion, and H. Sohn Novel and improved technologies for tuberculosis diagnosis: progress and challenges Clin Chest Med 30 2009 701 716
50. A. Lalvani, and K.A. Millington T-cell interferon-gamma release assays: can we do better? Eur Respir J 32 2008 1428 1430
51. M. Ruhwald, J. Petersen, and K. Kofoed Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test-based on IP-10 PLoS One 3 2008 e2858